December 4, 2020

Background: Throughout the COVID19 pandemic, massive efforts have been invested on the research of effective therapeutics.  Much of the research looks at repurposing older treatments (i.e. antimalarial drugs, antiviral agents, interleukin blockers and convalescent plasma therapy).  There have been no large randomized, controlled trials of targeted treatments specific to SARS-CoV-2. LY-CoV555 is an anti-spike protein neutralizing monoclonal antibody that binds with high affinity to the receptor-binding domain of SARS-CoV-2. Its role in treatment of COVID19 is unclear.

December 1, 2020

It is no secret we are in the middle of a pandemic, the likes of which our generation has never seen. Every day, clinicians care for thousands of patients infected with SARS-CoV2. One sick person can infect many more without proper precautions. Though we are making strides, progress is slow, and our efforts thus far have fallen short. The SARS-CoV-2 virus has proven to be quite a formidable and destructive opponent. However, a pandemic of misinformation can potentially be even more devastating.

November 29, 2020

Background: We have tried to decrease the number of updates on COVID-19, as I am sure everyone is getting tired of all the trials coming out on this.  I know I am exhausted just reading through everything.  However, every so often I will try to bring updates that are relevant.  In this post we will cover an interesting trial that should be on your radar as more evidence arises on this treatment option.

November 21, 2020

Background: Face masks can reduce transmission of respiratory viruses by both being a potential physical barrier and by reducing droplet transmission.  Additionally, the presence of a mask reduces the users frequency of touching their face which may also reduce transmission.  Despite strong, consistent public health messaging about the utility of wearing masks, their use continues to be debated. Both the CDC and WHO strongly recommend the use of masks as a means of source control, but the WHO acknowledges the lack of robust evidence in healthy persons.

November 13, 2020

Background: There have been lots of trials sitting on my computer desktop awaiting my review, but like many of you time has been thin from clinical work and increasing cases of COVID-19 where I work.  I thought it might be more effective to give you the Cliff’s Notes highlights of each since the time for deep dives remains elusive.  As always, I urge you to read each of the papers yourselves and come to your own conclusions. Thus far in the pandemic, there have been few treatment options available to manage COVID-19. Many clinicians have been using repurposed drugs with scant data as well as other non-drug interventions.  Let’s get into some recent data behind these interventions.
0